Physician profile
Michael R Martinez
NPI 1770924565
$2,269.29
in general payments reported to CMS, 2019-2025
15 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $179 · 2021: $402 · 2022: $408 · 2023: $221 · 2024: $436 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $460.66 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Biofinity Contact Lens |
| Alcon Vision LLC | $326.98 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $270.57 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $236.26 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Allergan, INC. | $221.82 | 2019-2022 | |
| Abbvie INC. | $190.31 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $170.31 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $139.91 | 2019-2023 | Tearcare System |
| Oyster Point Pharma, INC. | $56.71 | 2022 | |
| Dompe US, INC. | $53.25 | 2022-2025 | Oxervate |
| Glaukos Corporation | $38.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $35.43 | 2023 | |
| Abb Con-Cise Optical Group LLC | $31.86 | 2025 | Contact Lens |
| Johnson & Johnson Vision Care, INC. | $29.89 | 2020-2021 | |
| Lkc Technologies, INC. | $6.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.